Loading
Life sciences · Preprint
arXiv · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Whole-slide images may contain coexisting lesions, yet weak supervision typically provides only the most severe diagnosis. We formulate this setting as dominant-label multiple instance learning, where the observed label is the maximum-severity element of a latent lesion set. Standard multiclass MIL treats it as a complete one-hot description and therefore suppresses lower-severity evidence whenever it co-occurs with a dominant lesion. We propose DomSet-MIL, a label-aware framework that aligns the annotation mechanism across bag and instance levels. Dominant-Label Censored Likelihood models the reported diagnosis without declaring unreported lesions absent. Severity-Ordered Residual Routing assigns patch evidence from high to low severity and preserves residual support for secondary findings, while top-$q$ pooling links local routing scores to bag prediction. Experiments across natural and controlled settings show that DomSet-MIL achieves state-of-the-art performance in dominant-label prediction while more effectively recovering latent coexisting-lesion evidence. These findings demonstrate that modeling the dominant-label mechanism can improve diagnostic prediction without sacrificing clinically meaningful secondary findings.